Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary

Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary

Purpose: This study aimed to provide real-world evidence on the characteristics, treatment patterns, and outcomes of patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) treatment in Hungary between 2011 and 2019.Patients and methods: This nationwide, retrospective...

Full description

Bibliographic Details
Main Authors:	Peter Batar, Hussain Alizadeh, Gyorgy Rokszin, Zsolt Abonyi-Toth, Judit Demeter
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Pathology and Oncology Research
Subjects:	chronic myeloid leukemia real-word evidence tyrosine kinase inhibitors treatment outcome overall survival
Online Access:	https://www.por-journal.com/articles/10.3389/pore.2024.1611497/full

Similar Items

Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
by: Peter Batar, et al.
Published: (2024-03-01)

Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption
by: Judit Demeter, et al.
Published: (2021-02-01)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu, et al.
Published: (2020-02-01)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
by: Avital F. Barak, et al.
Published: (2011-12-01)

Assessment of chronic myeloid leukemia patients' adherence with “tyrosine kinase inhibitors” in King Abdulaziz Medical City
by: Saad Saleh Aldughaythir, et al.
Published: (2017-01-01)

Dissimilar impact of type 2 diabetes on cardiovascular outcomes according to age categories: a nationwide population study from Hungary
by: Zoltán Kiss, et al.
Published: (2018-07-01)

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
by: Petrushev B, et al.
Published: (2016-02-01)

Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
by: Olga Mulas, et al.
Published: (2021-09-01)

Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020—Nationwide Data from a Register-Based Analysis
by: György Jermendy, et al.
Published: (2022-10-01)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
by: Mario Tiribelli, et al.
Published: (2019-08-01)

Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
by: O. Y. Vinogradova
Published: (2015-10-01)

Changes in the incidence and prevalence of type 1 and type 2 diabetes among 2 million children and adolescents in Hungary between 2001 and 2016 – a nationwide population-based study
by: László Barkai, et al.
Published: (2019-12-01)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
by: Zhenshu Xu, et al.
Published: (2009-03-01)

Use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML)
by: C. B. Almeida, et al.
Published: (2016-11-01)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
by: Yundeok Kim, et al.
Published: (2021-11-01)

Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia
by: Miriam G. Contreras Mostazo, et al.
Published: (2020-11-01)

Neutrophil Extracellular Traps Are Increased in Chronic Myeloid Leukemia and Are Differentially Affected by Tyrosine Kinase Inhibitors
by: Alona Telerman, et al.
Published: (2021-12-01)

Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report
by: Michelle Hyunju Lee, et al.
Published: (2024-01-01)

Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
by: Franceli Carvalho, et al.
Published: (2016-12-01)

Features of the etythropoesis upon treatment of chronic myeloid leukemia with tyrosine kinase inhibitor
by: I. Sviezhentseva, et al.
Published: (2016-07-01)

Serum Calcium And Phosphateleveelsin Patients With Chronic Myeloid Leukemia Taking Different Dose of Tyrosine Kinase Inhibitors
by: Bassam Francis Matti, et al.
Published: (2018-03-01)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu
Published: (2013-09-01)

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
by: Gustavo P. Amarante-Mendes, et al.
Published: (2022-01-01)

Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors
by: Felipe Campos de Almeida, et al.
Published: (2022-04-01)

Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials
by: Fateen Ata, et al.
Published: (2023-12-01)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
by: Alessandra Iurlo, et al.
Published: (2021-02-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis
by: Olivia Kronick, et al.
Published: (2023-08-01)

Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study
by: Mehmet Özen, et al.
Published: (2017-02-01)

A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia
by: Nathan Cantoni, et al.
Published: (2022-11-01)

Comparative evaluation of bone marrow cells morpho-functional activity in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors of the first and second generation
by: I. O. Zhaleyko, et al.
Published: (2014-07-01)

Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
by: Prahathishree Mohanavelu, et al.
Published: (2021-04-01)

The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
by: Erin Clapper, et al.
Published: (2021-05-01)

Front-Line Tyrosine Kinase Inhibitors in Pediatric Chronic Myeloid Leukemia: A Study on Efficacy and Safety
by: Jae Won Yoo, et al.
Published: (2023-07-01)

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
by: Valentín García-Gutiérrez, et al.
Published: (2020-07-01)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
by: Asako Takeuchi, et al.
Published: (2021-01-01)

Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study
by: Tomohiro Kaneko, et al.
Published: (2023-02-01)

Evaluation of tyrosine kinase inhibitor discontinuation initiative in patients with chronic myeloid leukemia at princess noorah oncology center
by: Afnan Mohammed Noor, et al.
Published: (2022-01-01)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
by: Gabriel Etienne, et al.
Published: (2019-09-01)

The eosinophilic variant of chronic myeloid leukemia
by: Stephen E. Langabeer
Published: (2021-11-01)